The symptoms and course of schizophrenia are variable, without forming distinct familial subtypes.[@R1] There are positive (delusions, hallucinations), negative (reduced emotions, speech, interest) and disorganized symptoms (disrupted syntax and behavior), as well as mood symptoms in many cases. Onset is typically in adolescence or early adulthood, and rarely in childhood. Course of illness can range from acute episodes with primarily positive symptoms to the more common chronic or relapsing patterns often accompanied by cognitive disability and histories of childhood conduct or developmental disorders.

To search for common schizophrenia susceptibility variants, we carried out a GWAS in cases from three methodologically similar National Institute of Mental Health repository-based studies, and screened controls from the general population. Cases were included with diagnoses of schizophrenia or (in 10% of cases) schizoaffective disorder with the schizophrenia syndrome present for at least six months, genotyped with the Affymetrix 6.0 array. Because the frequencies of tag SNPs and disease susceptibility alleles can vary across populations, we carried out a primary analysis of the larger MGS European-ancestry sample (2,681 cases, 2,653 controls) and then additional analyses of the African American sample (1,286 cases, 973 controls) and of both of these samples combined, to test the hypothesis that there are alleles that influence susceptibility in both populations. All association tests were corrected using principal component scores indexing subjects' ancestral origins. Genotypic data were imputed for additional HapMap SNPs in selected regions.

These analyses did not produce genome-wide significant findings at a threshold of *P* \< 5 × 10^−8^ (see [Supplementary Methods](#SD1){ref-type="supplementary-material"}, p. S16). [Table 1](#T1){ref-type="table"} summarizes the best results in the European-ancestry and African American analyses. The strongest genic findings were in CENTG2 (chromosome 2q37.2, *P*=4.59E-07) in European-ancestry subjects, and in ERBB4 (2q34, *P*=2.14E-06) in African Americans. Common variants in ERBB4 (the strongest signal in African American subjects) and its ligand neuregulin 1 (NRG1) have been reported to be associated with schizophrenia.[@R3] Additional information about results in previously-reported schizophrenia candidate genes is provided in [Supplementary Results 3](#SD1){ref-type="supplementary-material"} and [Supplementary Datafile 2](#SD1){ref-type="supplementary-material"}.

As shown in online [Table S17](#SD1){ref-type="supplementary-material"}, power was adequate in the MGS European-ancestry sample to detect very common risk alleles (30--60% frequency, log additive effects) with genotypic relative risks (GRR) of approximately 1.3, with lower power in the smaller African American sample. The results suggest that there are few or no single common loci with such large effects on risk. The lack of consistency between the European-ancestry and African American analyses could be due to low power, but novel genome-wide analyses presented in the companion paper by the International Schizophrenia Consortium (discussed further below) suggest that while there is substantial overlap between the sets of risk alleles that are detected by GWAS in pairs of European-ancestry samples, much less overlap is seen between European-ancestry and African American samples. This could be because there are actually major differences between the sets of segregating common disease variants in these two populations, and/or because many risk variants are tagged by different GWAS markers or not adequately tagged by the GWAS array, which has poorer coverage of alleles that are more frequent in African populations. The hypothesis underlying our combined analysis, on the other hand, was that there could also be allelic effects common to these populations.

For many common diseases, common risk alleles with GRRs in the range of 1.1--1.2 have been detected when samples were combined to create much larger datasets.[@R4] Therefore, we carried out a meta-analysis of European-ancestry data with two other large studies: the International Schizophrenia Consortium (ISC) (3,322 cases, 3,587 controls) and the SGENE Consortium (2,005 cases, 12,837 controls). Note that because the Aberdeen sample was part of both the ISC and SGENE consortia, Aberdeen data were excluded from SGENE association tests for the meta-analysis. To rapidly identify the regions containing the strongest findings across the three studies (which used several Affymetrix and Illumina genotyping platforms), each group created a list of the SNPs with the best *P*-values in its final analysis (e.g., those with *P*\<0.001 in MGS), and provided the other groups with its *P*-values for the SNPs on their lists, based on genotyped or imputed data or data for the best proxy based on LD. Based on these initial results, all available data for genotyped SNPs and imputed HapMap II SNPs were then shared for regions of interest, of which four emerged from the European-ancestry data: 1p21.3 (PTBP2), 4q33 (NEK1), 6p22.1-6p21.31 (extended MHC region) and 18q21.2 (TCF4). We then combined *P*-values for all SNPs in each region by appropriately weighting *Z*-scores for sample size, accounting for the direction of association in each sample.

In the meta-analysis of European-ancestry MGS, ISC and SGENE datasets, seven SNPs on chromosome 6p22.1 yielded genome-wide significant evidence for association. These SNPs span 209 kb and are in strong LD (r^2^\>0.9), with substantial LD across 1.5 Mb ([Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Because of the strong LD among these SNPs, it is unclear whether the signal is driven by one or several genes, by intergenic elements, or by longer haplotypes that include susceptibility alleles in many genes. The region includes several types of genes of potential interest. The strongest evidence for association was observed in and near a cluster of histone protein genes, which could be relevant to schizophrenia through their roles in regulation of DNA transcription and repair[@R5],[@R6] or their direct role in antimicrobial defense.[@R7] Other genes in the broad region are involved in chromatin structure (HMGN4), transcriptional regulation (ABT1, ZNF322A, ZNF184), immunity (PRSS16; the butyrophilins[@R8]), G-protein-coupled receptor signaling (FKSG83) and in the nuclear pore complex (POM121L2), although the functions of many genes in the region (and of intergenic sequence variants) are not well understood.

*P*-values less than 10^−7^ were also observed in the meta-analysis in HLA-DQA1 (*P* = 6.88 × 10^−8^, [Table 2](#T2){ref-type="table"}), suggesting autoimmune mechanisms. This gene is in the class II HLA region, which is not in LD with 6p22.1 in the MGS sample. We note also that the MGS GWAS (see [Supplementary Datafile 1](#SD1){ref-type="supplementary-material"}, European-ancestry results) produced some evidence for association in the FAM69A-EVI-RPL5 gene cluster which has been implicated in multiple sclerosis, a DQA-associated auto-immune disorder.[@R9]

Finally, in an analysis reported in the companion paper by the International Schizophrenia Consortium, case-control status in the MGS sample could be predicted with very strong statistical significance based on an aggregate test of large numbers of common alleles, weighted by their odds ratios in the single-SNP association analysis of the ISC sample (please see the ISC paper for details). As expected, results were similar for an analysis with MGS as the discovery sample and ISC as the target (see [Supplementary Results 3](#SD1){ref-type="supplementary-material"}). As discussed in the ISC paper, the results suggest that a substantial proportion of variance may be explained by many common variants, most of them with small effects that cannot be detected one at a time.

We have identified a region of association of common SNPs with schizophrenia on chromosome 6p22.1. Further research will be required to identify the sequence variation in this region that alters susceptibility, and the mechanisms by which this occurs. The results of this meta-analysis and of the aggregate analysis of multiple alleles reported in the ISC paper strongly suggest that individual common variants have small effects on schizophrenia risk, and that still larger samples may be valuable. The larger goal of research in the field will be to detect and understand the full range of rare and common sequence and structural schizophrenia susceptibility variants. Association findings will advance knowledge of pathophysiological mechanisms, even if they initially explain small proportions of genetic variance. Future advances in knowledge of gene and protein functions and interactions should make it possible to dissect the functional sets of pathogenic variants based on prior hypotheses.

Methods summary {#S1}
===============

Details of MGS subject recruitment and sample characteristics are provided in the online [Full Methods](#SD1){ref-type="supplementary-material"} (section A1). DNA samples were genotyped using the Affymetrix 6.0 array at the Broad Institute. Samples (5.3%) were excluded for high missing data rates, outlier proportions of heterozygous genotypes, incorrect sex or genotypic relatedness to other subjects. SNPs (7% for African American, 25% for European-ancestry and 27% for combined analyses) were excluded for minor allele frequencies less than 1%, high missing data rates, Hardy-Weinberg deviation (controls), or excessive Mendelian errors (trios), discordant genotypes (duplicate samples) or large allele frequency differences among DNA plates. Principal component scores reflecting continental and within-Europe ancestries of each subject were computed and outliers excluded. Genomic control λ values for autosomes after QC were 1.042 for African American and 1.087 for the larger European-ancestry and combined analyses.

For MGS, association of single SNPs to schizophrenia was tested by logistic regression (trend test) using PLINK[@R10], separately for European-ancestry, African American and combined datasets, correcting for principal component scores that reflected geographical gradients or that differed between cases and controls, and for sex for chromosome X and pseudoautosomal SNPs. Genotypic data were imputed for 192 regions surrounding the best findings, and for additional regions selected for meta-analysis.[@R11] Detailed results are available in [Supplementary Datafiles 1 and 2](#SD1){ref-type="supplementary-material"}, and complete results from dbGAP ([www.ncbi.nlm.nih.gov/sites/entrez?db=gap](http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap)).

Meta-analysis of the MGS, ISC and SGENE datasets was carried out by combining *P*-values for all SNPs (in the selected regions) for which genotyped or imputed data were available for all datasets, with weights computed from case-control sample sizes. See the companion papers for details of the ISC and SGENE analyses.
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![Chromosome 6p22.1 Genetic association and linkage disequilibrium results in European-ancestry samples\
Genome-wide significant evidence for association (*P* \< 5 × 10^−8^, threshold shown by solid red line, SNPs by large red diamonds) was observed at 7 SNPs across 209 kb. *P*-values are shown for all genotyped and imputed SNPs (25,900,000--27,875,000 bp) for the meta-analysis of European-ancestry MGS, ISC and SGENE samples (8,008 cases, 19,077 controls). Red circles indicate other SNPs with *P* \< 5 × 10^−7^. Not shown are two SNPs in HLA-DQA1 (6p21.32; lowest *P* = 6.88 × 10^−8^, 32,710,247 bp; see [Supplementary Datafile 1](#SD1){ref-type="supplementary-material"}). Locations are shown for RefSeq genes and POM121L2. Pairwise LD relationships are shown for 26 SNPs with *P* \< 10^−7^ (except that SNPs 5 and 6 are shown, despite slightly larger *P*-values, to illustrate LD for that segment; and a SNP in strong LD with SNPs 25 and 26 is omitted). LD was computed from MGS European-ancestry genotyped and imputed SNP data. The signal is poorly localized because of strong LD: of the 7 significant SNPs, 7--8 and 9--11 are in nearly perfect LD; they are in or within \~ 30--50 kb of a cluster of 5 histone genes (HIST1H2BJ, HIST1H2AG, HIST1H2BK, HIST1H4I, HIST1H2AH; 27,208,073--27,223,325 bp). These SNPs are in moderately strong LD (r^2^ = 0.52--0.77) with 2 other significant SNPs 70--140 kb away, upstream of PRSS16 (SNP 13) or between PRSS16 and POM121L2 (SNP18). (See [Table 2](#T2){ref-type="table"} and [Supplementary Figures S10--11](#SD1){ref-type="supplementary-material"} for additional details.)](nihms123666f1){#F1}

###### 

MGS GWAS results

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP          Chromosome/\   Location\   Odds\   P-value    Gene(s)                          Function/relevance
               Band           (BP)        Ratio                                               
  ------------ -------------- ----------- ------- ---------- -------------------------------- -----------------------------------------------------------------------------------------
                                                             **European-ancestry analysis**   

  rs13025591   2q37.2         236460082   1.225   4.59E-07   CENTG2                           GTPase activator; deletions reported in autism cases.[@R12]

  rs16941261   15q25.3        86456524    1.255   8.10E-07   NTRK3                            Tyrosine receptor kinase; MAPK signaling.

  rs10140896   14q31.3        88288291    1.216   9.49E-07   EML5                             Microtubule assembly.

  rs17176973   5p15.2         10864474    1.679   2.16E-06                                    (50 kb upstream of DAP; mediates interferon-gamma-induced cell death)

  rs17833407   9p21.3         21738320    0.804   3.02E-06                                    (54 kb upstream of MTAP; enzyme involved in polyamine metabolism)

  rs1635239    Xp22.33        3242699     0.790   3.04E-06   MXRA5                            Cell adhesion protein.

  rs915071     14q12          31503609    0.834   3.94E-06                                    (102 kb downstream of NUBPL; nucleotide binding protein-like)

  rs11061935   12p13.33       1684035     0.773   4.06E-06   ADIPOR2                          Adiponectin (antidiabetic drug) receptor.

  rs6809315    3q13.11        107360155   0.828   7.58E-06                                    

  rs1864744    14q31.3        88020759    0.828   7.59E-06   PTPN21                           Regulation of cell growth and differentiation.

  rs1177749    10q23.33       97887981    0.835   1.29E-05   ZNF518                           Regulation of transcription.

  rs17619975   6p22.3         15510731    0.611   1.49E-05   JARID2                           Neural tube formation; histone demethylase; adjacent to DTNBP1 (candidate gene).

                                                                                              

                                                             **African American analysis**    

  rs1851196    2q34           212178865   0.733   2.14E-06   ERBB4                            Neuregulin receptor.

  rs3751954    17q25.3        75368080    0.528   4.59E-06   CBX2                             Polycomb protein; histone modfications, maintenance of transcriptional repression.

  rs10865802   3p24.2         25039902    1.330   6.73E-06                                    

  rs17149424   9q34.13        134523705   1.680   8.00E-06   DDX31                            RNA helicase family; embryogenesis.

  rs2162361    10q23.31       90037689    2.020   9.19E-06   C10orf59                         Degrades catecholamine *in vitro.*

  rs17149524   9q34.13        134546628   1.642   9.59E-06   GTF3C4                           Required for RNA polymerase III function.

  rs2587562    8q13.3         73153592    1.301   1.56E-05   TRPA1                            Cannabinoid receptor (cannabis may ↑ schizophrenia risk [@R1]); pain, sound perception.

  rs4316112    8p12           32539889    0.564   1.59E-05   NRG1                             Neuregulin 1; schizophrenia candidate gene; neuronal development.

  rs4732838    8p21.1         28098106    0.768   1.68E-05   ELP3                             Histone acetyltransferase, RNA Pol III elongator.

  rs9927946    16p13.2        8990868     0.718   1.70E-05                                    (26 kb upstream of UPS7; ubiquitin fusion protein cleavage; induction of apoptosis).

  rs13065441   3q26.2         172478029   0.626   1.94E-05   TNIK                             Stress-activated serine/threonine kinase

  rs2729993    8p12           34116593    0.687   2.14E-05                                    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Shown are the top 12 results (excluding duplicates \-- SNPs in the same genes or regions with less significant results) of the MGS European-ancestry (2681 cases, 2653 controls) and African American (1286 cases, 973 controls) MGS GWAS analyses. Listed are genes within 10 kb of the SNP and annotated information on possible functional relevance; or (in parentheses), information on genes within 150 kb. The odds ratio is for the tested allele (see [Supplementary Datafile 2](#SD1){ref-type="supplementary-material"}). [Supplementary Datafile 1](#SD1){ref-type="supplementary-material"} contains results for all SNPs with *P* \< 0.001, and full gene names. Results of an additional exploratory analysis that combined the two datasets are summarized in [Supplementary Results B1b, Table S18 and Supplementary Datafile 1](#SD1){ref-type="supplementary-material"}.

###### 

Meta-analysis results in the extended MHC I and MHC class II regions

                                        MGS Freqs   \-\-\-\-\-\-\-\-\-\-\-\-\-\-\--P-values\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--   \-\-\--Odds Ratios\-\-\--   \-\-\-\--Information\-\-\-\--                                                                                   
  ------------ ------- ---------- ----- ----------- ------------------------------------------------------------------------ --------------------------- ------------------------------- ---------- ---------- ------- ------- ------- ------- ------- ------- --------- ---------------------------------
  rs6939997    1       25929203   T/C   0.089       0.080                                                                    4.90E-07                    1.40E-01                        5.66E-04   2.85E-04   0.900   0.785   0.712   0.978   0.851   0.955   6p22.2    SLC17A1 (intr)
  rs13199775   2       25936761   T/A   0.087       0.075                                                                    1.19E-07                    5.12E-02                        5.66E-04   2.57E-04   0.869   0.785   0.710   0.999   0.851   0.956   6p22.2    SLC17A1 (intr)
  rs9461219    3       25944906   G/C   0.087       0.075                                                                    4.72E-07                    4.99E-02                        2.68E-03   2.52E-04   0.868   0.826   0.710   1.000   1.000   0.956   6p22.2    SLC17A1 (up),SLC17A3 (dwn)
  rs9467626    4       25981725   A/C   0.091       0.080                                                                    1.65E-07                    5.32E-02                        7.47E-04   2.68E-04   0.872   0.784   0.710   0.988   0.806   0.959   6p22.2    SLC17A3 (intr)
  rs2072806    5       26493072   G/C   0.115       0.097                                                                    9.27E-07                    5.91E-03                        2.80E-04   3.40E-02   0.836   0.814   0.857   0.959   1.000   0.971   6p22.1    BTN3A2 (dwn),BTN2A2 (intr)
  rs2072803    6       26500494   C/G   0.115       0.097                                                                    8.19E-07                    5.53E-03                        2.80E-04   3.23E-02   0.835   0.814   0.856   0.960   1.000   0.974   6p22.1    BTN2A2 (intr bound),BTN3A1 (up)
  rs6904071    7       27155235   A/G   0.186       0.166                                                                    ***1.78E-08***              1.21E-02                        3.03E-04   3.72E-04   0.879   0.819   0.799   0.987   0.851   0.988   6p22.1    
  rs926300     8       27167422   T/A   0.186       0.166                                                                    ***1.06E-08***              1.22E-02                        3.03E-04   2.08E-04   0.879   0.819   0.791   0.989   0.851   0.988   6p22.1    
  rs6913660    9       27199404   A/C   0.184       0.164                                                                    ***2.36E-08***              1.71E-02                        3.03E-04   3.35E-04   0.884   0.819   0.798   0.998   0.851   1.000   6p22.1    HIST1H2AG (up),HIST1H2BJ (dwn)
  rs13219181   10      27244204   G/A   0.183       0.163                                                                    ***1.29E-08***              1.47E-02                        3.03E-04   2.05E-04   0.881   0.819   0.791   0.983   0.851   0.989   6p22.1    
  rs13194053   11      27251862   C/T   0.182       0.162                                                                    ***9.54E-09***              1.45E-02                        3.03E-04   1.48E-04   0.880   0.819   0.783   0.977   0.851   0.978   6p22.1    
  rs13219354   12      27293643   C/T   0.118       0.102                                                                    1.12E-07                    3.59E-02                        5.11E-04   4.39E-04   0.877   0.823   0.766   0.994   1.000   1.000   6p22.1    
  rs3800307    13      27293771   A/T   0.205       0.183                                                                    ***4.35E-08***              1.34E-02                        3.35E-03   6.12E-05   0.886   0.880   0.787   1.000   1.000   0.988   6p22.1    
  rs13212921   14      27313401   T/C   0.124       0.108                                                                    1.28E-07                    3.09E-02                        5.76E-04   5.53E-04   0.873   0.823   0.770   0.960   0.940   0.968   6p22.1    
  rs4452638    15      27337244   A/G   0.117       0.102                                                                    2.68E-07                    4.51E-02                        3.96E-04   1.11E-03   0.882   0.821   0.780   1.000   1.000   0.987   6p22.1    PRSS16 (dwn)
  rs6938200    16      27339129   G/A   0.205       0.188                                                                    3.02E-07                    5.28E-02                        2.40E-03   1.51E-04   0.910   0.874   0.801   1.000   0.992   1.000   6p22.1    PRSS16 (dwn)
  rs6932590    17      27356910   C/T   0.240       0.215                                                                    7.13E-08                    3.37E-03                        2.23E-03   8.48E-04   0.872   0.877   0.834   0.973   0.933   1.000   6p22.1    
  rs3800316    18      27364081   C/A   0.257       0.229                                                                    ***3.81E-08***              7.19E-04                        3.51E-03   1.09E-03   0.856   0.886   0.834   0.975   0.956   0.977   6p22.1    
  rs7746199    19      27369303   T/C   0.185       0.160                                                                    5.03E-08                    6.85E-04                        8.77E-04   5.70E-03   0.837   0.859   0.839   1.000   1.000   1.000   6p22.1    
  rs3800318    20      27371620   T/A   0.180       0.158                                                                    6.38E-08                    2.80E-03                        8.82E-04   2.27E-03   0.855   0.859   0.822   0.998   1.000   0.981   6p22.1    
  rs16897515   21      27385999   A/C   0.173       0.154                                                                    1.83E-07                    1.22E-02                        6.40E-04   2.16E-03   0.876   0.853   0.816   1.000   1.000   0.972   6p22.1    POM121L2 (missense)
  rs13195040   22      27521903   G/A   0.087       0.076                                                                    2.50E-07                    1.04E-01                        3.00E-05   2.82E-03   0.892   0.714   0.768   1.000   1.000   0.983   6p22.1    ZNF184 (dwn)
  rs10484399   23      27642507   G/A   0.091       0.080                                                                    3.50E-07                    1.09E-01                        8.58E-06   8.69E-03   0.895   0.762   0.795   1.000   1.000   1.000   6p22.1    
  rs17693963   24      27818144   C/A   0.101       0.085                                                                    2.81E-07                    2.87E-02                        6.00E-05   8.85E-03   0.864   0.781   0.795   1.000   0.993   0.986   6p22.1    
  rs7776351    25      27834710   T/C   0.255       0.236                                                                    3.22E-07                    2.83E-02                        1.13E-04   6.51E-03   0.905   0.855   0.865   1.000   1.000   1.000   6p22.1    
  rs12182446   26      27853717   A/G   0.247       0.227                                                                    4.77E-07                    2.99E-02                        7.17E-05   1.22E-02   0.905   0.850   0.874   0.999   1.000   0.990   6p22.1    
                                                                                                                                                                                                                                                                         
  rs9272219    \-\--   32710247   T/G   0.283       0.263                                                                    6.88E-08                    1.32E-02                        2.24E-05   1.03E-02   0.897   0.847   0.880   1.000   1.000   0.977   6p21.32   HLA-DQA1 (up)
  rs9272535    \-\--   32714734   A/G   0.283       0.263                                                                    8.87E-08                    1.63E-02                        2.47E-05   9.92E-03   0.900   0.848   0.879   1.000   1.000   0.977   6p21.32   HLA-DQA1 (intr)

"\#" refers to the numbering of SNPs in the LD diagram in [Figure 1](#F1){ref-type="fig"}. "BP" = base pairs. "A1/2" = alleles 1 and 2 (minor/major, forward strand). "Freqs" = minor allele frequencies. "Cont" = controls, "Case" = cases. "COMB" = combined analysis (meta-analysis) of the three datasets. For SNP locations (as reported by snpper.chip.org): "intr"=intron; "up" = upstream (within 10 kb of transcribed sequence) and "dwn"=downstream (within 10 kb); "intr bound" = intron-exon boundary.

Shown are data for all SNPs with *P* \< 10^−6^ in the extended MHC I and class II MHC regions of chromosome 6p, in the meta-analysis of European-ancestry MGS, ISC and SGENE data (see [Table 1](#T1){ref-type="table"} and [Supplementary Methods](#SD1){ref-type="supplementary-material"}). Odds ratios are reported for the minor allele. Genome-wide significant meta-analysis *P*-values (*P* \< 5x10^−8^) are shown in ***bold italics***(see [Supplementary Methods](#SD1){ref-type="supplementary-material"}, p. S16, regarding this threshold). The information content for the SNP for each study is the imputation r^2^ reported by MACH 1.0 for MGS; and the PLINK and IMPUTE information measure for ISC and SGENE respectively; "1.000" indicates a SNP that was genotyped or had a perfect proxy. Genes within 10 kb of a SNP are listed; see [Figure 1](#F1){ref-type="fig"} for additional details for 6p22.1. See [Supplementary Datafile 1](#SD1){ref-type="supplementary-material"} for additional meta-analysis results.
